Gland Pharma Ltd.
NSE: GLANDGland Pharma Ltd.: A 30-second snapshot
Gland Pharma at Rs 1,904 is an NSE-listed injectable pharmaceutical manufacturer with 5-year revenue and earnings CAGRs of 22.5% and 27.8% respectively, though these growth figures have been delivered inconsistently with a consistency score of 20/100 and ROE above 15% in only 1 year. The stock trades above its 50-DMA of Rs 1,735 and 200-DMA of Rs 1,827 with a 35.4% gain over 12 months, while a debt-to-equity of 3.16 on a rising trend signals increasing financial leverage.
P/E
37.3
Forward P/E
26.8
ROE
—
Debt / Equity
3.16
Profit Margin
+13.9%
Div. Yield
+0.9%
5Y ROE > 15%
1/5
5Y FCF > 0
4/5
Quality
52/100
News
8 headlines · 5 positive · 0 negative
Gland Pharma Ltd stock (INE025W01027): USFDA nod for glaucoma drug lifts shares in India - AD HOC NEWS
AD HOC NEWS
Orbicular, Gland Pharma and Apotex secure US FDA approval for generic INFUVITE ADULT injectable - Express Pharma
Express Pharma
Sun Pharma, Aurobindo, Gland Pharma Among ICICI Securities' Seven Top Picks Ahead of Q4 Results — Check Target Prices - NDTV Profit
NDTV Profit
Gland Pharma Reappoints Naina Lal Kidwai as Independent Director for Second Term - Medical Dialogues
Medical Dialogues
Gland Pharma, IPCA Labs, Avantel, TII: Stocks to trade — Check target prices, stop loss - Business Today
Business Today
Recent context
- ·USFDA granted approval for Gland Pharma's glaucoma drug in May 2026, extending its US generics footprint; the company also co-secured approval for the INFUVITE ADULT injectable alongside Orbicular and Apotex.
- ·ICICI Securities included Gland Pharma among seven pharma picks ahead of Q4 results in an April 2026 note alongside Sun Pharma and Aurobindo — this reflects a third-party broker view and not a VivaTrades assessment.
- ·The stock gained 35.4% over 12 months but only 0.78% in the past 3 months, with RSI at 66.3 and the nearest resistance at Rs 1,985, approximately 4.2% above the current price of Rs 1,904.
Strengths
- +5-year earnings CAGR of 27.8% and revenue CAGR of 22.5% demonstrate above-average top and bottom-line compounding over the medium term.
- +Stock ranks 1st out of 6 on quality score (54) among its Pharma peer group, ahead of Sun Pharma at 50 and well above Cipla at 30 and Dr. Reddy's at 32.
- +Price is above both the 50-DMA at Rs 1,735 and 200-DMA at Rs 1,827, and the 52-week drawdown from the high is contained at -9.8%, reflecting relative price resilience.
- +Recent USFDA approvals including a glaucoma drug and the INFUVITE ADULT injectable signal continued regulatory traction in the US generics pipeline.
Weaknesses
- −Debt-to-equity of 3.16 with a confirmed rising debt trend is elevated for a pharma manufacturer and amplifies vulnerability to any revenue shortfall or working-capital disruption.
- −ROE has exceeded 15% in only 1 of the measured years and the consistency score of 20/100 indicates the high growth CAGRs have not been delivered with predictable regularity.
- −Profit margin of 13.86% is modest within pharma manufacturing and leaves limited buffer against raw-material cost inflation, currency headwinds, or US pricing pressure on generics.
- −FCF was positive in 4 of the measured years but the rising debt trend suggests capex or working-capital needs have periodically outpaced internal cash generation.
Open questions
- ?Does the elevated debt-to-equity ratio of 3.16 reflect deliberate capacity expansion that will translate into future revenue, or does it represent structural working-capital strain in a competitive generics business?
- ?How much of the 5-year earnings CAGR of 27.8% is attributable to US market access via Fosun Pharma's distribution network, and what is the concentration risk if that relationship changes?
- ?Given that ROE exceeded 15% in only 1 year despite strong topline growth, is the business model generating returns above the cost of capital at current leverage levels?
- ?The consistency score of 20/100 and profit margin of 13.86% — how do these compare to Gland Pharma's own historical range, and is the trajectory improving or deteriorating?
Peer comparison: Pharma
Ranks 1 of 6 on quality| Symbol | Name | P/E | ROE | Quality |
|---|---|---|---|---|
| GLAND | Gland Pharma Ltd.You're viewing | 37.3 | — | 54 |
| Industry avg | across 5 peers | 43.8 | +16.1% | 42 |
| MAXHEALTH | Max Healthcare Institute Ltd. | 71.2 | — | 54 |
| SUNPHARMA | Sun Pharmaceutical Industries Ltd. | 41.2 | — | 50 |
| APOLLOHOSP | Apollo Hospitals Enterprise Ltd. | 64.4 | — | 42 |
| DRREDDY | Dr. Reddy's Laboratories Ltd. | 18.8 | +16.1% | 32 |
| CIPLA | Cipla Ltd. | 23.2 | — | 30 |
Technical state
Current price
₹1,904.40
SMA 50
₹1,735.07
SMA 200
₹1,826.86
RSI (14)
66.3 (neutral)
From 52w high
-9.8%
1Y return
+35.4%
3M return
+0.8%
50-DMA
Above
200-DMA
Above
Algorithmic support levels
Algorithmic resistance levels
Risk flags
- mediumROE data is unavailable for the current period; the only available persistence metric shows ROE above 15% in just 1 of the measured years, indicating the company has not demonstrated sustained high-return equity deployment.
- mediumDebt-to-equity ratio stands at 3.16, elevated for a pharma manufacturer; persistence data confirms a rising debt trend, amplifying balance-sheet risk relative to peers in a capital-intensive regulatory environment.
- mediumConsistency score of 20 out of 100 and FCF-positive in only 4 years reflects uneven earnings quality; profit margin of 13.86% is modest by pharma standards and offers limited buffer against cost or pricing headwinds.
- lowAnalyst rating data is unavailable (count = 13 but no consensus rating reported), limiting visibility into how sell-side coverage is distributed; peer ROE and 1Y price-change data are missing for most comparables, reducing the reliability of relative-quality rankings.
- lowRSI of 66.3 is approaching overbought territory; stock has rallied 35.4% over 12 months and trades above both the 50-DMA at Rs 1,735 and 200-DMA at Rs 1,827, compressing the margin between current price of Rs 1,904 and nearest resistance at Rs 1,985.
Cross-section contradictions
- Strong 5-year revenue CAGR of 22.5% and earnings CAGR of 27.8% coexist with a consistency score of only 20/100 and ROE above 15% in just 1 year, suggesting growth has been delivered with high variability and capital intensity rather than compounding at high returns.
- News sentiment is uniformly positive with 5 positive and 0 negative across 8 articles, yet the stock has gained only 0.78% over the past 3 months despite a strong 12-month return of 35.4%, indicating positive news flow has not translated into near-term price momentum.
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 24 Jun 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 12 May 2026 · rotates through NIFTY 500 every ~5 days